Nusinersen sodium

诺西那生钠

Report date: 2026/05/23 20:00:57
NMEFirst In Class

Base Information

Drug NameNusinersen sodium
Drug Alias Name诺西那生IONIS-SMNRxISIS-SMNRxNusinersenSpinraza +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionSurvival motor neuron protein stimulants
TargetsSurvival motor neuron protein
Therapy Area/IndicationsMuscular Atrophy, Spinal
Global Approved IndicationsMuscular Atrophy, Spinal
Approved Indications in ChinaMuscular Atrophy, Spinal
Original Approved Country/TerritoryUnited States
Original Approved Date2016/12/23
Country/TerritoryBelgiumCanadaUnited States +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiogen Idec Research LtdBiogen Netherlands BvBiogen Inc +[7] 
Inactive CompaniesN/A
Active IndicationsMuscular Atrophy, Spinal
Inactive IndicationsN/A

Other Information

ATC CodeM09AX07
Related LinksWikipediaDrugBankKEGG